Please login to the form below

Not currently logged in
Email:
Password:

Novartis in health technology assessment trial with NICE

Novartis is collaborating with the UK's medicines agency, the National Institute of Health and Clinical Excellence on the joint design of a late-stage clinical trial to assess efficacy and health economics of a new drug

According to the UK newspaper The Financial Times, Swiss-headquartered Novartis has collaborated with the UK's medicines agency, the National Institute of Health and Clinical Excellence (NICE) on the joint design of a late-stage clinical trial.

According to the 17 December article, NICE will charge a fee for informing Novartis which criteria will form the basis of its decision to advise the NHS whether to buy the medicine once it is launched.

In an interview with the FT, Joe Jimenez, Novartis' head of pharmaceuticals, said: "This is about identifying the impact of the drug and the evidence of impact. Input at an early stage gives us the evidence to speed our drug to market. We're looking at more innovative ways to stand behind our drugs."

In November 2007, Novartis consulted with NICE on the design of the phase III trial for the drug, which is currently named Novartis 001.

According to the FT, the results of the trial are expected within a year.

19th December 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...
ABPI2018
The NHS and ABPI at 70: inching closer to the triple win
The NHS and UK pharma’s ABPI both turn 70 this year. After years of transactional relationships, there’s a will to work more closely - but friction on prices and value...
What pharma marketers can learn from behavioural science
Pharma behavioural science and traditional emotional marketing create a powerful mix of techniques that have impact on real lives....

Infographics